Reports Q revenue $10.3M, consensus $13.12M."2022 was an important year for Denali, marked by transition to late-stage clinical development in our therapeutic programs for Parkinson’s, MPS II, and ALS, as well as expansion of our Transport Vehicle (TV)-enabled portfolio with first-in-human studies in programs for FTD-GRN and Alzheimer’s," said Ryan Watts, Ph.D., Denali’s Chief Executive Officer. "We remain focused on progressing our broad and diversified therapeutic portfolio, further validating and expanding our TV platform, and building commercial capabilities with the ultimate goal of delivering effective medicines to people living with neurodegenerative and lysosomal storage diseases worldwide."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNLI:
- 3 Stocks to Buy Today, 2/28/2023, According to Top Analysts
- Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
- Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
- Cantor Fitzgerald biotech analysts to hold analyst/industry conference call
